擅长领域： 

执业经历： 职 称：副研究员 　　职 务：药学部主任助理 　　院 区：东院 　　科 室：药剂科 　　医疗专长：自获得第一个上海市教委优秀青年教师科学基金开始(2009年)，将研究集中具有用药复杂、社会负担重的疾病为研究对象，以运筹统计和临床决策为研究手段，以评价和比较不同治疗药物的成本及效果效用为目标开展工作。 　　教育经历 　　2013/09 – 2014/09，多伦多大学Leslie Dan药学院与多伦多大学附属总医院(学习) 　　2005/09 – 2008/06，上海交通大学，博士 　　2002/09 – 2005/06，中国科学院上海药物研究所，硕士， 　　1997/09 – 2002/06，南京医科大学 本科 　　论文著作 　　1.期刊论文(SCI收录第一作者/通讯作者)： 　　[1]. Wu B, Dong B, Xu Y, Zhang Q, Shen J, Chen H, Xue W: Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PLoS One 2012, 7(3):e32530. (IF = 3.73) 　　[2]. Wu B, Chen H, Shen J, Ye M: Cost-Effectiveness of Adding Rh-Endostatin to First-Line Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer in China. Clin Ther 2011, 33(10):1446-1455. (IF = 2.23) 　　[3]. Wu B, Ye M, Chen H, Shen JF: Costs of Trastuzumab in Combination With Chemotherapy for HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: An Economic Evaluation in the Chinese Context. Clin Ther 2012, 34(2):468-479. (IF = 2.23) 　　[4]. Wu B, Miao Y, Bai Y, Ye M, Xu Y, Chen H, Shen J, Qiu Y: Subgroup economic analysis for glioblastoma in a health resource-limited setting. PLoS One 2012, 7(4):e34588. (IF = 3.73) 　　[5]. Wu B, Li T, Chen H, Shen J: Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis. Value in Health 2010, 13(5):592-600. (IF = 2.191) 　　[6]. Wu B, Wilson A, Wang F-F, Wang S-L, Wallace DJ, Weisman MH, et al. Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china. PLoS One. 2012; 7(10): e47373. (IF = 3.73) 　　[7]. Y. Bai, M. Ye, H. Cao, X. Ma, Y. Xu and Wu B *. Economic evaluation of radiotherapy for early breast cancer after breast-conserving surgery in a health resource-limited setting, Breast cancer research and treatment 136 (2012), pp. 547-557. (Corresponding author) (IF = 4.469) 　　[8]. Wu B, J. Shen and H. Cheng, Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China, BMC Health Serv Res 12 (2012), p. 385. (IF = 1.773) 　　[9]. J. Zhu, T. Li, X. Wang, M. Ye, J. Cai, Y. Xu and Wu B *. Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis. BMC Cancer 2013, 13:39. (Corresponding author) (IF = 3.333) 　　[10]. Ben-Juan Wei, Yi-Jun Chen, Li Yu , Wu B. Periodontal Disease and Risk of Preeclampsia: A Meta-Analysis of Observational Studies. PLoS One. 2013. Doi:10.1371/journal.pone.0070901. (IF = 3.73) 　　[11]. Wu B, Kun L, Liu X, He B: Cost-Effectiveness of Different Strategies for Stroke Prevention in Patients with Atrial Fibrillation in a Health Resource-Limited Setting. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2013. 2013 Sep 19. [Epub ahead of print]. PMID: 24048510 (IF = 2.673) 　　获得荣誉 　　① 吴斌,林厚文, Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B, 中国药学会，优秀论文二等奖，2013.11 　　② 吴斌,叶明, Initial Chemotherapy with or without Maintenance Therapy in Patients with Advanced Non-Small-Cell Lung Cancer: An Economic Decision Analysis, 中国药学会，优秀论文二等奖，2012.11 　　③ 吴斌,吕良敬, Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china, 中华医学会，风湿病2012年会优秀论文三等奖, 2012.5 　　④ 吴斌, 类风湿关节炎患者使用生物制剂治疗的经济学研究, 上海市药学会，医院药学2012年会优秀论文三等奖, 2012.5 　　⑤ 吴斌, Subgroup economic analysis for glioblastoma in a health resource-limited setting, 上海市药学会，医院药学2010年会优秀论文一等奖，2010.11 　　⑥ 吴斌, 中国乙肝患者使用口服核苷类似物治疗的药物经济学研究, 上海交通大学医学院，医院药学2010年会优秀论文一等奖, 2010.12 　　⑦ 吴斌,邱永明, 脑胶质瘤治疗的药物经济学决策路径研究, 中华医学会，国际神经外科2010年会优秀论文三等奖, 2010.9 　　⑧ 吴斌,沈金芳, Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis, 中国药学会，优秀论文三等奖，2012.11 详细介绍